| HOME >> BIOLOGY >> TECHNOLOGY |
NANJING, China, April 27 /PRNewswire-FirstCall/ -- Sinobiopharma Inc. ("Sinobiopharma ", or "the Company") (OTC Bulletin Board: SNBP) is pleased to announce that it has secured rights to seven key patents from Company CEO Dr. Lequn Huang and the patents' co-holders. The patents that will significantly enhance Sinobiopharma's ability to execute on its mission of bringing safe, low-cost, high-efficacy biopharmaceuticals to market.
The patents are for the following:
Sinobiopharma will be applying these patents as well as using its own innovative applications of them in new drug development.
About Sinobiopharma
Sinobiopharma Inc. is a fully integrated and highly innovative biotechnology company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, the world's fastest growing pharmaceutical market. Known as Dong Ying (Jiangsu) Pharmaceutical Co. Ltd. in China, the Company's current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs.
FORWARD LOOKING STATEMENTS
This news release may include "forward-looking statements" regarding Sinobiopharma, Inc., and its subsidiaries, business and project plans. Such forward looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United States Secu
'/>"/>
| SOURCE Sinobiopharma, Inc. Copyright©2009 PR Newswire. All rights reserved |